Karyopharm Therapeutics, an early-stage biotech developing treatments for cancer by targeting nuclear transport, raised $109 million by offering 6.8 million (up from 5.7 million) shares at $16, the high end of the range of $14 to $16. Karyopharm Therapeutics plans to list on the NASDAQ under the symbol KPTI. Karyopharm Therapeutics initially filed confidentially on 9/5/2013. BofA Merrill Lynch and Leerink Swann acted as joint bookrunners on the deal.
